Seeking Alpha
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

Navidea reports preliminary 2014 revenue

On a preliminary basis, Navidea Biopharmaceuticals (NYSEMKT:NAVB) generated $6.3M in total revenue in 2014, including $4.2M for Lymphoseek(technetium Tc 99m tilmanocept). For Q4, the results were $2.2M and $1.5M, respectively. Gross profit was $4.7M and $1.9M, respectively. Read more